rss icon

Sunday, 23 December 2012 23:09

Joseph Papa, Chairman, President and CEO, Perrigo Co.

Written by  MiBiz Staff
Rate this item
(0 votes)
Joseph Papa, Chairman, President and CEO, Perrigo Co. MIBIZ FILE PHOTO: Russ Climie
Perrigo reported sales growth of 15.1 percent to $3.17 billion for its 2012 fiscal year. New products accounted for half of that sales growth. After launching more than 45 products this year, the generic and over-the-counter drug maker plans an even more ambitious schedule in 2013.

"The need for quality, affordable health care is essential to the well-being of all. As the economic recovery struggles and disposable incomes wane, consumers continue to seek value alternatives to higher-priced national brands. Health care reform also presents unique challenges and opportunities to the generic industry. As the health care industry continues the process of reform, equally effective affordable generics look to benefit from price-conscious consumers seeking to stretch their dollars without sacrificing quality.

"Perrigo is well-positioned to continue the rapid growth the company has experienced over the last five years. With our recent expansion into the pet care field, our continued efforts to build infrastructure in foreign markets, and the release of approximately 60 new products this fiscal year, we continue to show our dedication to growth while providing consumers better value and high quality products. As Perrigo celebrates its 125th anniversary, we believe our strong fundamentals and the diversification of our ever-growing product portfolio will guide us through whatever 2013 brings.”

Read 2041 times Last modified on Thursday, 20 December 2012 20:24

Breaking News

September 2018
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 1 2 3 4 5 6

Follow MiBiz